The Journal of Medical Microbiology, Vol 47, Issue 12 1115-1122, Copyright © 1998 by Society for General Microbiology

JOURNAL ARTICLE

Comparative susceptibilities of various AIDS-associated and human urogenital tract mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro

P. C. Hannan
Mycoplasma Experience Ltd, Reigate, Surrey.

The susceptibilities of 40 strains of various Mycoplasma species to 10 classes of antimicrobial agents were compared in vitro by a broth microdilution method. The strains tested comprised 20 strains of four AIDS-associated species--M. penetrans (1 strain), M. fermentas (5 strains), M. pirum (6 strains) and M. genitalium (8 strains)--nine strains of the urogenital tract species M. hominis and 11 strains of M. pneumoniae. The results demonstrated wide variation in the susceptibilities of the different Mycoplasma spp. to different classes of antimicrobial agent. All the mycoplasmas were susceptible or highly susceptible to the fluoroquinolones, with sparfloxacin the most active, and to the diterpine antibiotic tiamulin. M. pneumoniae and M. genitalium strains were also highly susceptible to the macrolides, particularly azithromycin and had similar antibiotic susceptibility patterns to most other antimicrobial agents. However, all strains of M. genitalium were resistant to streptomycin (MIC 250->500 mg/L) whereas all M. pneumoniae isolates, except the MAC strain, were susceptible (MICs 1.25-12.5 mg/L). M. pirum isolates varied considerably in their susceptibility to macrolides (MIC range versus azithromycin 0.0025->100 mg/L). M. fermentans strains were susceptible to the tetracyclines, lincosamides and mupirocin, but varied in susceptibility to aminoglycosides. Most M. hominis strains were susceptible to the tetracyclines and all were susceptible to clindamycin and mupirocin. M. penetrans GTU 54 was susceptible to azithromycin, the tetracyclines and lincosamides as well as to the fluoroquinolones and tiamulin.

This article has been cited by other articles:

				E Bjornelius, C Anagrius, G Bojs, H Carlberg, G Johannisson, E Johansson, H Moi, J S Jensen, and P Lidbrink Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial Sex. Transm. Inf., February 1, 2008; 84(1): 72 - 76. [Abstract] [Full Text] [PDF]

				A Wikstrom and J S Jensen Mycoplasma genitalium: a common cause of persistent urethritis among men treated with doxycycline. Sex. Transm. Inf., August 1, 2006; 82(4): 276 - 279. [Abstract] [Full Text] [PDF]

				S. V. Hjorth, E. Bjornelius, P. Lidbrink, L. Falk, B. Dohn, L. Berthelsen, L. Ma, D. H. Martin, and J. S. Jensen Sequence-Based Typing of Mycoplasma genitalium Reveals Sexual Transmission. J. Clin. Microbiol., June 1, 2006; 44(6): 2078 - 2083. [Abstract] [Full Text] [PDF]

				R. Hamasuna, Y. Osada, and J. S. Jensen Antibiotic Susceptibility Testing of Mycoplasma genitalium by TaqMan 5' Nuclease Real-Time PCR Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4993 - 4998. [Abstract] [Full Text] [PDF]

				L Falk, H Fredlund, and J S Jensen Tetracycline treatment does not eradicate Mycoplasma genitalium Sex. Transm. Inf., August 1, 2003; 79(4): 318 - 319. [Abstract] [Full Text] [PDF]

				G. E. Kenny and F. D. Cartwright Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2604 - 2608. [Abstract] [Full Text] [PDF]

				P. C. T. Hannan and G. Woodnutt In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas J. Antimicrob. Chemother., March 1, 2000; 45(3): 367 - 369. [Abstract] [Full Text] [PDF]

				S. Johnson, D. Sidebottom, F. Bruckner, and D. Collins Identification of Mycoplasma fermentans in Synovial Fluid Samples from Arthritis Patients with Inflammatory Disease J. Clin. Microbiol., January 1, 2000; 38(1): 90 - 93. [Abstract] [Full Text]